Last Updated: Monday, 17-Dec-2012 17:00:00 EST
Update from Europe on HoFH Drug
On Dec. 13, the European Medicines Agency announced that it failed to grant marketing approval for Kynamro (mipomersen sodium) due to concerns about its side effects. Kynamro has been in the Sanofi/Isis Pharmaceuticals pipeline as a therapy intended to treat homozygous FH. The drug is under development by Genzyme, which is owned by Sanofi. In October, the U.S. FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 9-6 in favor of the treatment. The U.S. FDA is expected make a decision on Kynamro by the end of January 2013. For more information, please click here to read the Bloomberg news article.